Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLINICAL-EVALUATION OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH-FACTOR FOR THE TREATMENT OF LOWER-EXTREMITY DIABETIC ULCERS
Autore:
STEED DL; WEBSTER MW; RICOTTA JJ; LUTERMAN A; BROWN S; COMEROTA AJ; WALSH DB; BERGAMINI TM; BAKER WH; BOLTAX RS; SCHWARCZ TH; DONOHOE DJ; FLEISHMAN A; KRUPSKI WC; HARRINGTON ME; GIBBONS G; LOGERFO F;
Indirizzi:
UNIV PITTSBURGH,PRESBYTERIAN UNIV HOSP A1011 PITTSBURGH PA 15213
Titolo Testata:
Journal of vascular surgery
fascicolo: 1, volume: 21, anno: 1995,
pagine: 71 - 81
SICI:
0741-5214(1995)21:1<71:CORHPG>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
OXYGEN-TENSION MEASUREMENTS; CHRONIC NONHEALING WOUNDS; GRANULATION-TISSUE; HEALING FACTORS; FACTOR-BB; STIMULATION; BIOLOGY; REPAIR; SKIN; PRESSURE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
D.L. Steed et al., "CLINICAL-EVALUATION OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH-FACTOR FOR THE TREATMENT OF LOWER-EXTREMITY DIABETIC ULCERS", Journal of vascular surgery, 21(1), 1995, pp. 71-81

Abstract

Purpose: The purpose of this study was to investigate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) in a double-blind, placebo-controlled, multicenter study of patients with chronic diabetic ulcers. Methods: Patients with chronic, full-thickness, lower-extremity diabetic neurotrophic ulcers of at least 8 weeks' duration, free of necrotic and infected tissue after debridement, and with transcutaneous oxygen tensions of 30 mm Hg or greater were studied. A total of 118 patients were randomized to receive either topical rhPDGF-BB (2.2 mu g/cm(2) of ulcer area) or placebo until the ulcer was completely resurfaced or for a maximum of 20 weeks, whichever occurred first. Results: Twenty-nine (48%) of 61 patients randomized tothe rhPDGF-BB group achieved complete wound healing during the study compared with only 14 (25%) of 57 patients randomized to the placebo group (p = 0.01). The median reduction in wound area in the group givenrhPDGF-BB was 98.8% compared with 82.1% in the group given placebo (p= 0.09). There were no significant differences in the incidence or severity of adverse events between the rhPDGF-BB and placebo groups. Conclusions: Once-daily topical application of rhPDGF-BB is safe and effective in stimulating the healing of chronic, full-thickness, lower-extremity diabetic neurotrophic ulcers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 01:23:45